Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

State Copay Accumulator Legislation: An Overview

Joseph Cantrell, JD  |  June 25, 2024

Key Features of State Copay Accumulator Laws

  1. Prohibition of copay accumulator programs. Twenty-one states have outright banned the use of copay accumulator programs. These laws mandate that any third-party payments, including manufacturer assistance, must be applied to a patient’s deductible and out-of-pocket maximums.
  2. Transparency and notification requirements. Other states focus on transparency, requiring insurers to clearly inform patients about the existence and impact of copay accumulator programs. These laws may not prohibit the programs but ensure patients are fully aware of how their copay assistance will be applied.
  3. Scope of legislation. Legislation in different states varies in scope, affecting different plans. Some laws apply to all health plans within the state; others may apply only to plans sold through the state’s health insurance marketplace or may exempt specific insurance, such as Medicaid or state employee health insurance. Some legislation applies only to assistance from charitable organizations and not that from manufacturers.

Conclusion

State copay accumulator legislation represents a critical step in safeguarding patient access to necessary medications and ensuring that financial assistance reaches those who need it most. Although challenges remain, the continuing evolution of these laws reflects a commitment to patient-centered healthcare and equitable access to treatments. As more states consider and implement this legislation, the collective impact on public health could be substantial, paving the way for a more supportive and transparent healthcare system.

Page: 1 2 | Single Page
Share: 

Filed under:Uncategorized Tagged with:copay accumulatorsstate legislation

Related Articles

    A Primer on Copay Accumulator Programs

    June 17, 2022

    The growing use of copay accumulator programs, which restrict the application of patient assistance funds toward cost-sharing requirements, hurts patient access to life-changing treatments. This was one topic discussed during the ACR’s Advocacy Leadership Conference in D.C. this May.

    felipe caparros / shutterstock.com

    Copay Accumulator Programs Can Derail Rheumatologic Treatment Plans

    February 13, 2020

    As the medications for rheumatology become more expensive, the need for patient financial assistance becomes paramount. Unfortunately, commercially insured patients are finding it difficult to afford the exorbitant copays required by their plans, and the latest strategy of pharmacy benefit managers (PBMs) threatens to derail rheumatologic treatment goals. High deductible plans combined with copay accumulator…

    Copay Accumulator & Maximizer Programs Threaten Access to Treatment

    July 6, 2023

    As health insurance companies and third-party benefit managers continue to use copay accumulators and maximizers to shift the cost of specialty drugs to patients, the ACR continues to advocate against programs that limit copay assistance.

    ACR Leads Resolution to Address Copay Accumulator Policies at AMA House of Delegates Meeting

    November 6, 2020

    If passed, the ACR-authored resolution will direct the AMA to advocate for copay accumulator bans at state and federal levels. Several other specialties and state medical associations have joined the resolution as cosponsors.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences